(Q33898154)

English

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

Celestia Higano

9

object named as

Celestia S Higano

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

7

object named as

Peter S Nelson

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Evan Y Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Roman Gulati

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Donatello Telesca

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Peter Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Stephen Tam

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Kenneth J Russell

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ruth D Etzioni

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

26 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2668-2673

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2881848

5 July 2018

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20421544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20421544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20421544

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.25.1330

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33898154&oldid=2191542375"